Circulating chromogranin A and hormone refractory prostate cancer chemotherapy

Journal of Urology

Volumn 175, Issue 4, 2006, Pages 1347-1352

  Cabrespine, Aurélie ^a,b   Guy, Laurent ^d   Gachon, Françoise ^a   Curé, Hervé ^a,b,c   Chollet, Philippe ^a,b,c   Bay, Jacques Olivier ^a,c  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Chomotherapy; Chromogranin A; NEDF protein, human; Prostate; Prostatic neoplasms

Indexed keywords

CARBOPLATIN; CHROMOGRANIN A; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; HORMONAL THERAPY; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; PACLITAXEL; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 33644606173     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00640-3     Document Type: Article

References (20)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor Cancer statistics, 2005 CA Cancer J Clin 55 2005 10
2. M.B. Garnick Hormonal therapy in the management of prostate cancer from Huggins to the present Urology 49 suppl 1997 5
3. S. Urakami, M. Igawa, N. Kikuno, T. Yoshino, H. Kishi, K. Shigeno Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer J Urol 168 2002 2444
4. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502
5. N. Vashchenko, P.A. Abrahamsson Neuroendocrine differentiation in prostate cancer implications for new treatment modalities Eur Urol 47 2005 147
6. J. Hansson, P.A. Abrahamsson Neuroendocrine pathogenesis in adenocarcinoma of the prostate Ann Oncol 12 suppl 2001 S145
7. A. Angelsen, U. Syversen, O.A. Haugen, M. Stridsberg, O.K. Mjolnerod, H.L. Waldum Neuroendocrine differentiation in carcinomas of the prostate do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 30 1997 1
8. R. Ischia, A. Hobisch, R. Bauer, U. Weiss, R.W. Gasser, W. Horninger Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate J Urol 163 2000 1161
9. M. Ferrero-Pous, A.M. Hersant, A. Pecking, M. Bresard-Leroy, M.F. Pichon Serum chromogranin-A in advanced prostate cancer BJU Int 88 2001 790
10. G.J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461
11. A. Berruti, A. Mosca, M. Tucci, C. Terrone, M. Torta, R. Tarabuzzi Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease Endocr Relat Cancer 12 2005 109
12. O. Cussenot, J.M. Villette, A. Valeri, G. Cariou, F. Desgrandchamps, A. Cortesse Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma J Urol 155 1996 1340
13. D. Kadmon, T.C. Thompson, G.R. Lynch, P.T. Scardino Elevated plasma chromogranin-A concentrations in prostatic carcinoma J Urol 146 1991 358
14. G. Steineck, V. Reuter, W.K. Kelly, R. Frank, L. Schwartz, H.I. Scher Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements Acta Oncol 41 2002 668
15. P.A. di Sant'Agnese Neuroendocrine differentiation in prostatic carcinoma an update on recent developments Ann Oncol 12 suppl 2001 S135
16. A. Angelsen, H.L. Waldum, E. Brenna Neuroendocrine cells in prostatic carcinoma Hum Pathol 26 1995 1389
17. A.I. Evangelou, S.F. Winter, W.J. Huss, R.A. Bok, N.M. Greenberg Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype J Cell Biochem 91 2004 671
18. J. Kim, J.L. Palmer, L. Finn, S. Hodges, V.V. Bowes, L. Deftos The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate Urol Oncol 5 2000 97
19. A. Berruti, L. Dogliotti, A. Mosca, G. Gorzegno, E. Bollito, M. Mari Potential clinical value of circulating chromogranin A in patients with prostate carcinoma Ann Oncol 12 suppl 2001 S153
20. A.L. Iacangelo, L.E. Eiden Chromogranin A current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway Regul Pept 58 1995 65